Lacosamid 123 Acurae Pharma

Lacosamide, the active ingredient in Lacosamid 123 Acurae Pharma, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamid 123 Acurae Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant used in the management of seizure disorders, particularly focal epileptic activity. - Partial‑onset seizures: provides adjunctive seizure reduction when added to existing therapy. - Refractory epilepsy: helps control seizures in patients who have not responded adequately to other antiepileptic drugs. - Adjunctive treatment in adults and children with epilepsy: offers additional seizure control as part of a comprehensive regimen.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit. - Headache: mild to moderate cranial pain. - Somnolence: increased sleepiness during the day.

Serious or Rare Side Effects: - Cardiac arrhythmias: irregular heart rhythms, including PR‑interval prolongation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: thoughts of self‑harm or suicide. - Blood dyscrasias: abnormal blood cell counts. - Liver injury: elevated liver enzymes or hepatitis.

Before initiating therapy, consider the following safety measures. - Renal impairment: assess kidney function and adjust dosing as needed. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction abnormalities: obtain baseline ECG and monitor PR interval. - Pregnancy: risk unknown; use only if potential benefit justifies potential risk. - Concomitant CNS depressants: may increase sedation; monitor patient closely. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medications, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels. - Other sodium‑channel blockers (e.g., phenytoin, carbamazepine): increased risk of neurotoxicity. - Drugs that prolong PR interval (e.g., quinidine, amiodarone): may exacerbate cardiac conduction delays.

Moderate Interactions (Monitor Closely): - Oral contraceptives: lacosamide may reduce hormonal efficacy; consider alternative contraception. - Alcohol: combined use can enhance central nervous system depression. - Selective serotonin reuptake inhibitors (SSRIs): may increase dizziness or somnolence.